Genitourinary Cancers | Specialty

Exploring the "Dark Matter" in Prostate Cancer Genomics

September 14th 2016

Mark A. Rubin, MD, is an expert in prostate cancer genomics and pathology who has led key discoveries in the distinction between indolent and aggressive types of the malignancy.

Dr. Ball on Eventual Role of Immunotherapy in Patients With RCC

September 14th 2016

Mark Ball, MD, chief urology resident, Johns Hopkins University School of Medicine, discusses the eventual role that immunotherapy will play in the treatment landscape of renal cell carcinoma (RCC), as well as patient selection to receive immunotherapy as a single agent or in combination.

Obesity Paradox in RCC: Improved OS for Patients With High BMI

September 9th 2016

Evidence has demonstrated that obesity is a risk factor for clear cell renal cell carcinoma; however, a new report suggests that a high body mass index is a prognostic factor for improved survival in patients with metastatic RCC who have received targeted therapy.

Expert Discusses Evolving Roles of Cabozantinib, Nivolumab in RCC

September 8th 2016

Jorge A. Garcia, MD, discusses the final survival data from the phase III METEOR trial, which was the basis for cabozantinib's (Cabometyx's) FDA approval, as well as the role the agent will now play along with nivolumab (Opdivo) in advanced RCC.

Dr. McDermott on Major Findings of Efficacy and Safety of Nivolumab in RCC

September 7th 2016

David F. McDermott, MD, director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center, discusses the findings of the phase III CheckMate-025 trial of nivolumab (Opdivo) versus everolimus (Afinitor) in renal cell carcinoma (RCC).

Dr. Rafii on Future Immunotherapy Approaches for Patients With Bladder Cancer

September 2nd 2016

Saeed Rafii, MD, PhD, medical director, Sarah Cannon Research Institute, United Kingdom, discusses novel immunotherapy approaches for the treatment of patients with bladder cancer.

Dr. Blute on Kidney-Sparing Surgery Vs Radical Nephrectomy in RCC

September 1st 2016

Michael L. Blute, MD, chair of Department of Urology, Massachusetts General Hospital, discusses the differences between kidney-sparing surgery and radical nephrectomy for patients with renal cell carcinoma (RCC).

Dr. Nanus on Clinical Trials Exploring Immunotherapy in Bladder Cancer

August 29th 2016

David M. Nanus, MD, medical oncologist, Weill Cornell Medicine and NewYork-Presbyterian Hospital, discusses ongoing clinical trials exploring immunotherapy agents for the treatment of patients with bladder cancer.

Dr. Poch on Nivolumab as a Treatment for Patients With Bladder Cancer

August 26th 2016

Michael A. Poch, MD, urologist and assistant member at Moffitt Cancer Center, discusses the potential of nivolumab (Opdivo) as a treatment for patients with metastatic bladder cancer.

Dr. Lee on Nanotechnology Combination Therapy in RCC

August 24th 2016

Benjamin R. Lee, MD, chief, Division of Urology, University of Arizona College of Medicine-Tucson Department of Surgery, and director of the Genitourinary Cancer and Disease Oriented Strategic Planning Team, University of Arizona Cancer Center, discusses nanotechnology combination therapy for patients with renal cell carcinoma (RCC).

Immunotherapy Advances Offer New Hope in Bladder Cancer

August 24th 2016

Michael Poch, MD, provides deeper insight into how immunotherapy has propelled the field of bladder cancer forward, as well as the research that still needs to be done.

Researchers Poised to Expand on Exciting Advancements in RCC

August 24th 2016

Mayer Fishman, MD, discusses the therapeutic landscape in renal cell carcinoma and the next steps needed to further advance the field.

Dr. Elizabeth Plimack on Consideration Regarding Nivolumab in RCC

August 23rd 2016

Second-Line Therapies for mCRPC Complicated by Drug Interactions and Dosing Issues

August 18th 2016

Approximately 4 years after the FDA approval of 2 powerful new oral androgen-targeting agents for metastatic castration-resistant prostate cancer, an analysis raised issues complicating treatment with the 2 drugs, as well as what oncologists do not yet know.

Dr. Mohammed Haseebuddin on PD-1 Expression in RCC

August 17th 2016

Dr. Alexander I. Sankin on HHLA2 in Bladder Cancer

August 17th 2016

Dr. Fishman Discusses Available Agents to Treat Patients With RCC

August 16th 2016

Mayer Fishman, MD, PhD, medical oncologist, Chemical Biology and Molecular Medicine Program, Moffitt Cancer Center, professor, Department of Oncologic Sciences and of Internal Medicine, University of South Florida Morsani College of Medicine, discusses the available agents to treat patients with renal cell carcinoma.

Rio Grande Urology Expands With Gynecologic Oncology Collaboration

August 14th 2016

As a group, Rio Grande Urology shares a sense of obligation and culture. Its leaders have embraced an integrative model approach and sees the advantages of it.

Survival Improved With Surgery/Targeted Therapy Combo in Renal Cell Carcinoma

August 13th 2016

Patients with renal cancer who underwent cytoreductive nephrectomy and targeted therapy had improved survival compared with patients who did not undergo the surgery.

Expert Explores Next Steps With "Game Changer" Atezolizumab in Bladder Cancer

August 11th 2016

Gary D. Steinberg, MD, discusses the impact of atezolizumab (Tecentriq) on the treatment landscape of bladder cancer, the resistance to finding effective therapies for the disease, and what potential role immunotherapy may have in the field going forward.